Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...

Milestone Pharmaceuticals (MIST) announced that it has received Notice of Allowance from the United States Patent and Trademark Office, or ...

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat ...

Milestone Pharmaceuticals Inc. announced that the PDUFA date for its nasal spray CARDAMYST™ (etripamil) for treating Paroxysmal Supraventricular Tachycardia (PSVT) has been set for March 27 ...

Milestone Pharmaceuticals ... short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal ...

Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...

Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) is possibly approaching a major achievement in its business, so we would... - PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray ...

Rodman & Renshaw launched its coverage of Canadian biopharma Milestone Pharmaceuticals (NASDAQ ... lead candidate Cardamyst ...

MONTREAL and CHARLOTTE, N.C. - Milestone Pharmaceuticals Inc ... related to its lead investigational product, etripamil nasal spray, commercially known as CARDAMYST™. The company's stock ...